Researchers used whole-genome sequencing and droplet digital PCR to get a close-up look at how copy number in rDNA affects cellular function in cancer.
The partners aim to improve the ability to predict pancreatic cancer patients' responses to treatment.
Last week's buys of two oncology labs will allow Quest to provide new cancer diagnostic technologies to communities lacking major cancer research centers, it said.
The companies will evaluate Adaptive's ClonoSeq assay for monitoring minimal residual disease in multiple myeloma patients treated with Janssen's Darzalex.
While trials targeting actionable mutations are showing promise in some cancer cases, experts say such trials likely need to account for tumor heterogeneity.
Researchers shored up their age-specific breast and ovarian cancer risk estimates by following thousands of individuals with pathogenic BRCA1/2 mutations.
GeneStrat is a blood-based test using a droplet digital PCR platform that detects mutations relevant to patient treatment in non-small cell lung cancer.
Clinicians say they are using blood-based tests for patients who can't be biopsied as a way to get test results sooner, but implementing tests smartly and appropriately remains a challenge.
Under the terms of the deal, MDxHealth and QUT will evaluate and develop the test, which will evaluate abnormal DNA methylation changes.
The test is now CE marked for use in identifying patients with urothelial cancer who are most likely to benefit from Opdivo therapy.
New research has identified circulating cell subtypes with ties to better or worse outcomes in individuals with prostate cancer.
An international research team profiled more than 7,500 tumor genomes, including small-bowel adenocarcinoma, colorectal cancer, and gastric cancer genomes.
The companies are aiming to identify treatment-response biomarker signatures in patients with advanced melanoma.
The Brown University spinout wants to apply its algorithms to help improve personalized cancer treatments.
The company intends to use the funds to automate its platform and internationally commercialize its colorectal cancer detection assay.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
While Cynvenio will still perform testing in its own lab right now, the firm's CEO said that interested labs could move the technology in house in the future if they desire.
The company is testing the assay's potential as a tool to manage the treatment of patients with primary breast cancer.
The company has secured coverage for its pigmented lesion assay from CareFirst Blue Cross/Blue Shield and affiliate CareFirst BlueChoice.
Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.
DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.
A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.
In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.